Skin sensitization in silico protocol

Candice Johnson(LeadScope (United States)), Ernst Ahlberg(Uppsala University), Lennart T. Anger, Lisa Beilke, Romualdo Benigni, Joel P. Bercu(Gilead Sciences (United States)), Sol Bobst, David Bower(LeadScope (United States)), Alessandro Brigo(Roche (Switzerland)), Sarah Campbell(Nelson Engineering (United States)), M Cronin(Liverpool John Moores University), Ian Crooks(British American Tobacco (United Kingdom)), Kevin P. Cross(LeadScope (United States)), Tatyana Y. Doktorova(Edelweiss Connect (Switzerland)), Thomas E. Exner(Edelweiss Connect (Switzerland)), David Faulkner(Lawrence Berkeley National Laboratory), Ian M. Fearon, Markus Fehr(DSM (Switzerland)), Shayne C. Gad(Gad Consulting Services (United States)), Véronique Gervais(Servier (France)), Amanda Giddings(GlaxoSmithKline (United Kingdom)), Susanne Glowienke(Novartis (Switzerland)), Barry Hardy(Edelweiss Connect (Switzerland)), Catrin Hasselgren, Jedd Hillegass(Bristol-Myers Squibb (Germany)), Robert A. Jolly(Eli Lilly (United States)), Eckart Krupp(Sanofi (Germany)), Liat Lomnitski(Perrigo (Israel)), Jason Magby(Colgate-Palmolive (United States)), Jordi Mestres(Hospital Del Mar), Lawrence Milchak(3M (United States)), Scott A. Miller(LeadScope (United States)), Wolfgang Muster(Roche (Switzerland)), Louise Neilson, R. Parakhia(Church & Dwight (United States)), Alexis Parenty(Novartis (Switzerland)), Patricia Parris(Pfizer (United Kingdom)), Alexandre Tadeu Paulino, Ana Theresa Paulino, David W. Roberts(Nelson Engineering (United States)), Harald Schlecker(Bayer (Germany)), Reinhard Stidl, Diana Suarez-Rodrigez, David T. Szabo(PPG Industries (United States)), Raymond R. Tice(Robert Bosch (Germany)), Daniel Urbisch(Bristol-Myers Squibb (Netherlands)), Anna Vuorinen(DSM (Switzerland)), B. Wall(Colgate-Palmolive (United States)), Thibaud Weiler(Servier (France)), Angela White(GlaxoSmithKline (United Kingdom)), Jessica Whritenour(Pfizer (United States)), Joerg Wichard(Bayer (Germany)), David Woolley(Lawrence Berkeley National Laboratory), Craig Zwickl, Glenn J. Myatt(LeadScope (United States))
Regulatory Toxicology and Pharmacology
July 1, 2020
Cited by 46Open Access
Full Text

Abstract

The assessment of skin sensitization has evolved over the past few years to include in vitro assessments of key events along the adverse outcome pathway and opportunistically capitalize on the strengths of in silico methods to support a weight of evidence assessment without conducting a test in animals. While in silico methods vary greatly in their purpose and format; there is a need to standardize the underlying principles on which such models are developed and to make transparent the implications for the uncertainty in the overall assessment. In this contribution, the relationship between skin sensitization relevant effects, mechanisms, and endpoints are built into a hazard assessment framework. Based on the relevance of the mechanisms and effects as well as the strengths and limitations of the experimental systems used to identify them, rules and principles are defined for deriving skin sensitization in silico assessments. Further, the assignments of reliability and confidence scores that reflect the overall strength of the assessment are discussed. This skin sensitization protocol supports the implementation and acceptance of in silico approaches for the prediction of skin sensitization.


Related Papers

No related papers found

Powered by citation graph analysis